216 related articles for article (PubMed ID: 38332687)
1. Image-guided metabolomics and transcriptomics reveal tumour heterogeneity in luminal A and B human breast cancer beyond glucose tracer uptake.
Yang Q; Deng S; Preibsch H; Schade TC; Koch A; Berezhnoy G; Zizmare L; Fischer A; Gückel B; Staebler A; Hartkopf AD; Pichler BJ; la Fougère C; Hahn M; Bonzheim I; Nikolaou K; Trautwein C
Clin Transl Med; 2024 Feb; 14(2):e1550. PubMed ID: 38332687
[TBL] [Abstract][Full Text] [Related]
2. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.
Koo HR; Park JS; Kang KW; Cho N; Chang JM; Bae MS; Kim WH; Lee SH; Kim MY; Kim JY; Seo M; Moon WK
Eur Radiol; 2014 Mar; 24(3):610-8. PubMed ID: 24097303
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT.
Sasada S; Masumoto N; Suzuki E; Sueoka S; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):831-837. PubMed ID: 30648199
[TBL] [Abstract][Full Text] [Related]
6. Combined
Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
[TBL] [Abstract][Full Text] [Related]
7. Association between ¹⁸F-FDG uptake and molecular subtype of breast cancer.
Kitajima K; Fukushima K; Miyoshi Y; Nishimukai A; Hirota S; Igarashi Y; Katsuura T; Maruyama K; Hirota S
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1371-7. PubMed ID: 25947575
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
Humbert O; Berriolo-Riedinger A; Cochet A; Gauthier M; Charon-Barra C; Guiu S; Desmoulins I; Toubeau M; Dygai-Cochet I; Coutant C; Fumoleau P; Brunotte F
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):416-27. PubMed ID: 24258007
[TBL] [Abstract][Full Text] [Related]
9. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer.
Arslan E; Çermik TF; Trabulus FDC; Talu ECK; Başaran Ş
Nucl Med Commun; 2018 Jul; 39(7):680-690. PubMed ID: 29893750
[TBL] [Abstract][Full Text] [Related]
10. Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study.
Incoronato M; Grimaldi AM; Cavaliere C; Inglese M; Mirabelli P; Monti S; Ferbo U; Nicolai E; Soricelli A; Catalano OA; Aiello M; Salvatore M
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1680-1693. PubMed ID: 29696443
[TBL] [Abstract][Full Text] [Related]
11.
Wu J; Wang S; Zhang X; Teng Z; Wang J; Yung BC; Niu G; Zhu H; Lu G; Chen X
J Nucl Med; 2018 Dec; 59(12):1809-1816. PubMed ID: 29700127
[No Abstract] [Full Text] [Related]
12. Impact of physiological hormonal fluctuations on
Miyake KK; Nakamoto Y; Saji S; Sugie T; Kurihara K; Kanao S; Ikeda DM; Toi M; Togashi K
Breast Cancer Res Treat; 2018 Jun; 169(3):437-446. PubMed ID: 29423901
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study.
Tiling R; Linke R; Untch M; Richter A; Fieber S; Brinkbäumer K; Tatsch K; Hahn K
Eur J Nucl Med; 2001 Jun; 28(6):711-20. PubMed ID: 11440031
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using
Zhang J; Liu Y; Fan H; Wang W; Shao W; Cao G; Shi X
Acad Radiol; 2023 Sep; 30 Suppl 2():S82-S92. PubMed ID: 36624021
[TBL] [Abstract][Full Text] [Related]
15. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
16. 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.
Palaskas N; Larson SM; Schultz N; Komisopoulou E; Wong J; Rohle D; Campos C; Yannuzzi N; Osborne JR; Linkov I; Kastenhuber ER; Taschereau R; Plaisier SB; Tran C; Heguy A; Wu H; Sander C; Phelps ME; Brennan C; Port E; Huse JT; Graeber TG; Mellinghoff IK
Cancer Res; 2011 Aug; 71(15):5164-74. PubMed ID: 21646475
[TBL] [Abstract][Full Text] [Related]
17. Texture analysis of high-resolution dedicated breast
Moscoso A; Ruibal Á; Domínguez-Prado I; Fernández-Ferreiro A; Herranz M; Albaina L; Argibay S; Silva-Rodríguez J; Pardo-Montero J; Aguiar P
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):196-206. PubMed ID: 28936601
[TBL] [Abstract][Full Text] [Related]
18. 11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET.
Higashi K; Ueda Y; Matsunari I; Kodama Y; Ikeda R; Miura K; Taki S; Higuchi T; Tonami H; Yamamoto I
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):13-21. PubMed ID: 14574513
[TBL] [Abstract][Full Text] [Related]
19. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Dose-Schwarz J; Tiling R; Avril-Sassen S; Mahner S; Lebeau A; Weber C; Schwaiger M; Jänicke F; Untch M; Avril N
Br J Cancer; 2010 Jan; 102(1):35-41. PubMed ID: 19920815
[TBL] [Abstract][Full Text] [Related]
20. Molecular subtypes of breast cancer: metabolic correlation with ¹⁸F-FDG PET/CT.
García Vicente AM; Soriano Castrejón Á; León Martín A; Chacón López-Muñiz I; Muñoz Madero V; Muñoz Sánchez Mdel M; Palomar Muñoz A; Espinosa Aunión R; González Ageitos A
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1304-11. PubMed ID: 23632960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
